Module 1: Introduction (00:00:00 - 00:07:00)
Dr. Sameeksha Saxena Lamba (PT) from the Medical Learning Hub (MLH) team introduced and welcomed all the panelists and participants. The poll was raised. The structure of the webinar and the general instructions were shared with the participants.
Module 2: Welcome Address: Dr. Pankaj Bandarkar (00:07:00 - 00:08:34)
Dr. Pankaj Bandarkar, Secretary, IMA Maharashtra welcomed all the panelists and participants and introduced both the speakers of the event. Dr. Bandarkar shared how the second wave of COVID led to a surge in the case of Mucormycosis. Dr. Pankaj Bandarkar also thanked Mylan Pharmaceuticals and MLH for making this series of webinars a success.
Module 3: Comparing Liposomal and Conventional Amp B for Mucormycosis Treatment (00:08:34 - 00:24:50)
Dr. Prarthna Jagtap shares her thoughts and knowledge on the topic: Comparing Liposomal and Conventional Amp B for Mucormycosis Treatment.
Various aspects of the topic were covered including:
- Introduction.
- Etiology, Pathophysiology, and risk factors.
- COVID associated Mucormycosis.
- Mucormycosis signs and symptoms.
- Management ECMM/ISHAM Recommendations.
- Amphotericin B.
- Amphotericin B Preparations.
- First-line Antifungal options for the treatment of Mucormycosis.
- Adverse Drug Reactions.
- All the topics were covered in-depth and were well explained.
Module 4: Case presentation on treating Mucormycosis (00:24:50 - 00:54:04)
Dr. Harish Chafle, Pulmonologist, Critical Care Consultant, Global Hospitals, Parel, Mumbai started his session by thanking the Mylan Pharmaceuticals, IMA Maharashtra and MLH team for organizing this webinar on the topic: Case presentation on treating Mucormycosis. Dr. Chafle covered various aspects on the topic such as:
- Why is it important to know about Mucormycosis?
- Epidemiology of Mucormycosis in India.
- Case Presentation with details on treatment.
- When should one suspect Mucormycosis over Aspergillosis?
- Mucormycosis in India.
- Diabetes is a risk factor.
- Medical and surgical management of Mucormycosis.
- Adjunctive Treatment.
- Combination therapy.
- All the topics were covered in-depth and were well explained.
Module 5: Q&A (00:54:04 - 00:58:45)
Dr. Sameeksha Saxena Lamba (PT) from the Medical Learning Hub (MLH) team moderated the numerous questions that were asked by the participants throughout the session. All the questions were answered by the speakers. It was an extremely interactive session.
Module 6: Thank you note (00:58:45 - 01:04:54)
Dr. Mayuri Keskar and Dr. Sameeksha Saxena Lamba (PT) from team MLH thanked Mylan Pharmaceutical, IMA Maharashtra, and both the speakers for making this webinar a success. The post-poll was raised.
We thank Mylan Pharmaceuticals Private Limited, a Viatris Company making this event possible and we wish you all a great learning experience.
- Welcome Note: Dr Ramkrishna Londhe, President IMA MS
- Session 1: Comparing Liposomal and Conventional Amp B for Mucormycosis Treatment, Dr. Prarthna Jagtap, Senior Consultant Otorhinolaryngologist, Global Hospitals, Parel, Mumbai
- Session 2: Case presentation on treating Mucormycosis, Dr. Harish Chafle, Pulmonologist, Critical Care Consultant, Global Hospitals, Parel, Mumbai
- Vote of Thanks: from Dr Pankaj Bandarkar, IMA MS Secretary
